This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-08 and is reviewed periodically as new material appears.
Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.
Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.
The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
| Property | Value | Notes |
|---|---|---|
| Water content | Low in freshly lyophilised material | Rises after repeated opening of the same vial |
| Solution stability | Lower than powder stability | Frozen aliquots are preferred over repeated thawing |
| Purity assessment | Reversed-phase HPLC with UV detection | Peak-area percentage excludes salts and water |
| Salt form | Often the trifluoroacetate salt | Retained from acidic purification gradients |
| Light sensitivity | Not strongly photoreactive | Dark storage still advised for long-term keeping |
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Emily Maitlis, TV newscaster and reporter Winston Marshall (born 20 December 1987); journalist and podcaster; former Mumford & Sons musician; has written for Jewish Chronicle (on BDS), Daily Mail, Newsweek, Die Welt, Dissident Muse Journal, RealClear Politics, The Spectator, David Horowitz' Frontpage Magazine, Hot Press, Common Sense with Bari Weiss; has interviewed Eylon Levy, Natan Sharansky, Douglas Murray, mostly focusing on the Israel-Hamas conflict. Monty Meth (3 March 1926 – 14 March 2021) was a British journalist who was editor of the Daily Mail; was member of the Young Communist League;appointed Member of the Order of the British Empire (MBE) in the 2007 Queen's Birthday Honours for services to the communities of Enfield and Bethnal Green.; author of Here to Stay: A Study of Good Practices in the Employment of Coloured Workers 1972; Brothers to all Men? A Report on Trade Union Actions and Attitudes on Race Relations.
=== Arjo === Arjo was founded in 1957 by Arne Johansson in the Swedish town of Eslöv. The company name consists of the first two letters of the first and last name of the company founder. Arjo initially functioned as a supplier of components and machine parts to medical device manufacturers. In 1972, the company developed the first height-adjustable bathtub and introduced it to the market. In 1993, the company's shares are listed on the Stockholm Stock Exchange and the London Stock Exchange. In 1995, the company merged with the Swedish Getinge Group, in whose "Extended Care" business area it continued to operate under its brand name. In 2004, Arjo took over the company BHM Medical and rounded off its range of passenger lifts with its Ceiling Lifts.
=== Journey to Europe === For a few centuries, Europeans had experimented with American vines and plants in their soil. Many varieties were imported from America without regulation, disregarding the possibility of pest transfer and related problems. Jules-Emile Planchon, a French biologist who identified the Phylloxera in the 1860s, maintained that the transfer of American vines and plants into Europe greatly increased between roughly 1858 and 1862, and accidentally introduced Phylloxera to Europe around 1860. Others say that the aphid did not enter France until around 1863. The advent of steamships may have been a factor: as they were faster than sailing ships, the Phylloxera were better able to survive the shorter ocean voyage.
Further action is planned for Saturday, the day of the FA Cup Final, and on Friday by members of RMT. A huge wildfire covering 30 mi2 (78 km2), possibly the largest ever seen in the UK, is brought under control by the Scottish Fire and Rescue Service at Cannich in the Highlands.
== Applications to cryptography == The difficulty of protein sequencing was recently proposed as a basis for creating k-time programs, programs that run exactly k times before self-destructing. Such a thing is impossible to build purely in software because all software is inherently clonable an unlimited number of times.
Sources: en.wikipedia.org
=== In prokaryotes === In prokaryotes a small 30S ribosomal subunit contains the 16S ribosomal RNA. The large 50S ribosomal subunit contains two rRNA species (the 5S and 23S ribosomal RNAs). Therefore it can be deduced that in both bacteria and archaea there is one rRNA gene that codes for all three rRNA types :16S, 23S and 5S. Bacterial 16S ribosomal RNA, 23S ribosomal RNA, and 5S rRNA genes are typically organized as a co-transcribed operon. As shown by the image in this section, there is an internal transcribed spacer between 16S and 23S rRNA genes. There may be one or more copies of the operon dispersed in the genome (for example, Escherichia coli has seven). Typically in bacteria there are between one and fifteen copies. Archaea contains either a single rRNA gene operon or up to four copies of the same operon. The 3' end of the 16S ribosomal RNA (in a ribosome) recognizes a sequence on the 5' end of mRNA called the Shine-Dalgarno sequence.
Argentation chromatography is chromatography using a stationary phase that contains silver salts. Silver-containing stationary phases are well suited for separating organic compounds on the basis of the number and type of alkene groups. The technique is employed for gas chromatography and various types of liquid chromatography, including thin layer chromatography. Analytes containing alkene groups elute more slowly than the analogous compounds lacking alkenes. Separations are also sensitive to the type of alkene. The technique is especially useful in the analysis of fats and fatty acids, which are well known to exist in both saturated and unsaturated (alkene-containing) forms. For example, trans fats, undesirable contaminants in ultra-processed foods, are quantified by argentation chromatography.
Estramustine phosphate (EMP), also known as estradiol normustine phosphate and sold under the brand names Emcyt and Estracyt, is a dual estrogen and chemotherapy medication which is used in the treatment of prostate cancer in men. It is taken multiple times a day by mouth or by injection into a vein. Side effects of EMP include nausea, vomiting, gynecomastia, feminization, demasculinization, sexual dysfunction, blood clots, and cardiovascular complications. EMP is a dual cytostatic and hence chemotherapeutic agent and a hormonal anticancer agent of the estrogen type. It is a prodrug of estramustine and estromustine in terms of its cytostatic effects and a prodrug of estradiol in relation to its estrogenic effects. EMP has strong estrogenic effects at typical clinical dosages, and consequently has marked antigonadotropic and functional antiandrogenic effects. EMP was introduced for medical use in the early 1970s. It is available in the United States, Canada, the United Kingdom, other European countries, and elsewhere in the world.
== Similar approaches == Though immunoliposomes serve as a possible advancement, there are other therapies similar to it that trail on the role of targeted drug delivery systems. One example of such therapy is Immune Polymeric nanoparticles, which are similar to liposomes but consist of small particles composed of biodegradable polymers. These nanoparticles similarly encapsulate drugs and can function to enhance specificity towards targeted diseased cells with peptide ligands. Another type is Targeting Antibody Drug Conjugates, which combine monoclonal antibodies with the cytotoxicity of chemotherapy drugs. This specific type is catered towards cancer cells expressing a specific target antigen. They are well-tolerated by the body as they are biodegradable, eliminating many potential toxicity factors, and proving to be a possible new model for therapeutics.
{\displaystyle \mu ={\frac {1}{j+1}}{\Bigl \langle }(l,s),j,m_{j}{=}j\,{\Bigr |}\left({\frac {1}{2}}{\vec {l}}{g^{(l)}}_{p}+{\frac {1}{2}}{\vec {s}}({g^{(s)}}_{p}+{g^{(s)}}_{n})\right)\cdot {\vec {\jmath }}\,{\Bigl |}\,(l,s),j,m_{j}{=}j{\Bigr \rangle }}
Sources: en.wikipedia.org
== Medical uses == Fremanezumab is indicated for the preventive treatment of migraine in adults; and the preventive treatment of episodic migraine in children who are aged 6 to 17 years of age and who weigh 45 kilograms (99 lb) or more. Fremanezumab was shown to be effective in adults with four or more attacks per month.
In nuclear physics, beta decay (β-decay) is a type of radioactive decay in which an atomic nucleus emits a beta particle (fast energetic electron or positron), transforming into an isobar of that nuclide. For example, beta decay of a neutron transforms it into a proton by the emission of an electron accompanied by an antineutrino; or, conversely a proton is converted into a neutron by the emission of a positron with a neutrino in what is called positron emission. Neither the beta particle nor its associated (anti-)neutrino exist within the nucleus prior to beta decay, but are created in the decay process. By this process, unstable atoms obtain a more stable ratio of protons to neutrons. The probability of a nuclide decaying due to beta and other forms of decay is determined by its nuclear binding energy. The binding energies of all existing nuclides form what is called the nuclear band or valley of stability. For either electron or positron emission to be energetically possible, the energy release or Q value must be positive. Beta decay is a consequence of the weak force, which is characterized by relatively long decay times. Nucleons are composed of up quarks and down quarks, and the weak force allows a quark to change its flavour by means of a virtual W boson leading to creation of an electron/antineutrino or positron/neutrino pair. For example, a neutron, composed of two down quarks and an up quark, decays to a proton composed of a down quark and two up quarks.
VP-13 operating PB2Y-3s from 26 February to 22 June 1944 VP-16 operating PBM-3Ds from 7 June to 1 August 1944 VP-21 operating PBM-3Ds from 19 August to 17 October 1944 and from 15 July to 11 September 1945 VP-23 operating PBY-5As from 20 August 1944 to 9 April 1945 VP-MS-6 operating PBM-5Es from 1 February 1948 in support of Operation Sandstone VP-102 operating PB2Y-3s from 3 February to 30 August 1944 VP-202 operating PBM-3Ds from 24 February to 1 March 1944 VPB-19 operating PBM-3Ds from 2 November 1944 to 12 February 1945 and 6 March 1945 to January 1946 VPB-22 operating PBM-3Ds from 10 October to 30 November 1944 and from 25 June to 7 August 1945
=== Generics === Glaxo patents for sumatriptan expired in February 2009. At that time, Imitrex sold for about $25 a pill. Par Pharmaceutical then introduced generic versions of sumatriptan injection (sumatriptan succinate injection) 4 and 6 mg starter kits and 4 and 6 mg filled syringe cartridges, and 6 mg vials soon after. Mylan Laboratories Inc., Sun Pharma, Sandoz (a subsidiary of Novartis), Dr. Reddy's Laboratories, and other companies have been producing generic versions of sumatriptan tablets in 25, 50, and 100 mg doses. Generic forms of the drug are available in US and European markets after Glaxo's patent protections expired in the respective countries. A nasal spray form of sumatriptan known as AVP-825 has been developed by Avanir and is generically available in some countries.
Sources: en.wikipedia.org
Divide it into single-use aliquots and hold them frozen at -20 °C or below, protected from light. Repeated thawing of one container is the main avoidable source of variability.
Mass spectrometry confirms identity, because the measured mass is compared with the value expected from the sequence. Chromatography mainly reports how much of the material elutes as the target peak.
It usually describes the share of the chromatographic peak area recorded at a set wavelength. Salts, residual water, and solvent are excluded from that number, so it is not the same as mass fraction.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.